MX2023004832A - Método de administración segura del anticuerpo anti-tau. - Google Patents

Método de administración segura del anticuerpo anti-tau.

Info

Publication number
MX2023004832A
MX2023004832A MX2023004832A MX2023004832A MX2023004832A MX 2023004832 A MX2023004832 A MX 2023004832A MX 2023004832 A MX2023004832 A MX 2023004832A MX 2023004832 A MX2023004832 A MX 2023004832A MX 2023004832 A MX2023004832 A MX 2023004832A
Authority
MX
Mexico
Prior art keywords
tau antibody
tau
safe administration
antibody
bind
Prior art date
Application number
MX2023004832A
Other languages
English (en)
Spanish (es)
Inventor
Partha Nandy
Lingjue Li
David Henley
Ruixo Carlos Pérez
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2023004832A publication Critical patent/MX2023004832A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
MX2023004832A 2020-10-26 2021-10-25 Método de administración segura del anticuerpo anti-tau. MX2023004832A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063105810P 2020-10-26 2020-10-26
US202163250114P 2021-09-29 2021-09-29
PCT/EP2021/079566 WO2022090169A1 (en) 2020-10-26 2021-10-25 Method of safe administration of anti-tau antibody

Publications (1)

Publication Number Publication Date
MX2023004832A true MX2023004832A (es) 2023-07-18

Family

ID=78483271

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004832A MX2023004832A (es) 2020-10-26 2021-10-25 Método de administración segura del anticuerpo anti-tau.

Country Status (10)

Country Link
US (1) US20220127346A1 (https=)
EP (1) EP4232472A1 (https=)
JP (1) JP2023546503A (https=)
KR (1) KR20230097110A (https=)
AU (1) AU2021370222A1 (https=)
CA (1) CA3199808A1 (https=)
IL (1) IL302383A (https=)
MX (1) MX2023004832A (https=)
TW (1) TW202231661A (https=)
WO (1) WO2022090169A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3093200A1 (en) 2018-03-05 2019-09-12 Janssen Pharmaceutica Nv Anti-phf-tau antibodies and uses thereof
US20230235034A1 (en) * 2020-05-26 2023-07-27 The Trustees Of The University Of Pennsylvania Monoclonal antibodies against pathological tau, and methods using same
CA3199806A1 (en) * 2020-10-26 2022-05-05 Janssen Pharmaceutica Nv Methods of reducing tau in human subjects

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
TWI771389B (zh) * 2017-03-16 2022-07-21 美商健生生物科技公司 抗phf-tau抗體及其用途
US10646569B2 (en) * 2017-05-16 2020-05-12 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity

Also Published As

Publication number Publication date
CA3199808A1 (en) 2022-05-05
AU2021370222A1 (en) 2023-06-22
KR20230097110A (ko) 2023-06-30
IL302383A (en) 2023-06-01
WO2022090169A1 (en) 2022-05-05
JP2023546503A (ja) 2023-11-02
TW202231661A (zh) 2022-08-16
US20220127346A1 (en) 2022-04-28
EP4232472A1 (en) 2023-08-30

Similar Documents

Publication Publication Date Title
MX2023004832A (es) Método de administración segura del anticuerpo anti-tau.
JP2018505882A5 (https=)
RU2017134443A (ru) Способ лечения с применением традипитанта
JP2016514132A5 (https=)
AR095338A1 (es) Método de tratamiento no tóxico para la abstinencia de drogas
JP2018507243A5 (https=)
TN2022000113A1 (en) Dosing regimen for anti-dll3 agents
JOP20210284A1 (ar) الإعطاء غير المتجانس للقاحات تاو
RU2014127298A (ru) Применения иммуноконъюгатов, мишенью которых является cd138
BR112022009283A2 (pt) Métodos de tratamento do câncer do pulmão de células pequenas com formulações de lurbinectedina
ZA202000028B (en) Use of vibegron to treat overactive bladder
JP2018531605A5 (https=)
JP2019511506A5 (https=)
FI3359572T3 (fi) Menetelmä multippeliskleroosin hoitamiseksi
MX2026000276A (es) Composiciones y metodos para tratar la esclerosis multiple
NZ781127A (en) Mirikizumab for use in a method of treating crohn’s disease
Kim et al. Optimal level of tacrolimus to prevent acute graft-versus-host disease
EA201692107A1 (ru) Схема лечения тиакумициновым соединением
NZ781127B2 (en) Mirikizumab for use in a method of treating crohn's disease
PE20252784A1 (es) Composiciones y metodos para administrar paltusotina a pacientes con insuficiencia hepatica
Bäckman et al. Conversion from Twice (Prograf) to Once Daily Administration of Tacrolimus (Advagraf) Regimen in Renal or Liver Transplant Recipients; An Open Multicenter Trial: 665
Todeschini et al. Advagraf vs. Prograf as Immunosuppressive Therapy in De Novo Renal Transplant Immunosuppressive Therapy: A Single Centre Experience: 714
Kim et al. Comparison Between Horse and Rabbit Antithymocyte Globulin as an Induction Agent in Kidney Transplantation: A Single Center Experience: 695
WO2024206868A3 (en) Methods of treating tumors with anti-tigit antibodies
NZ773583A (en) Methods of treating psoriasis